Last updated on April 20, 2014 at 21:20 EDT

Elsevier Launches European Journal of Cancer iPad Edition

September 26, 2011

OXFORD, England, September 26, 2011 /PRNewswire/ –

                         EJC App Now Available on the App Store

Elsevier, a world-leading provider of scientific, technical and medical
information products and services, today announced the launch of the iPad
edition of the European Journal of Cancer (EJC). Starting with the September
2011 issue, all 18 annual issues of the EJC will be available through the
EJC App on the App Store. iPad editions feature the same high quality
articles that are published in the print as well as online editions.

The EJC App includes published content from the highly popular EJC News
and EJC News Focus, and offers readers the ability to customize the journal
by selecting articles, tables, or figures to store and use later, as well as
making notes on articles.

“We are proud that the EJC is the first European oncology journal to
launch an iPad edition,” said Alexander Eggermont, Editor-in-Chief of the
EJC. “It is important for our readers to have access to the journal whenever
they need it. The iPad editions deliver the EJC to them in an easy to use
format, straight to their device.”

The EJC App offers unprecedented portability to its readers, who can
download the edition wirelessly. It is then available for reading and
browsing offline, at times and in places where web access is not available.
Of perhaps most significance, the journal can be read the same way on iPad
as in print. The reader can flip pages forward and backward in the
horizontal plane and scroll down vertically to read an individual article.

The EJC App [http://itunes.apple.com/us/app/ejc-app/id461022524?mt=8 ]
is available for free from the App Store.

About the European Journal of Cancer

The EJC, with an Impact Factor of 4.944, is an international
multidisciplinary oncology journal that publishes original research,
editorial comments, review articles and news on basic and preclinical
research, clinical oncology (medical, paediatric, radiation, surgical),
translational oncology, and on cancer epidemiology and prevention. Led by
Editor-in-Chief, Alexander Eggermont, the EJC is the official journal of the
EORTC (the European Organisation for Research and Treatment of Cancer, ECCO
(the European CanCer Organisation), the EACR (European Association for
Cancer Research), and EUSOMA (the European Society of Breast Cancer

About Elsevier

Elsevier is a world-leading provider of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet [http://www.thelancet.com ] and Cell
[http://www.cell.com ], and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
SciVerse ScienceDirect [http://www.sciencedirect.com ], SciVerse Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Nursing Consult
[http://www.nursingconsult.com ], which enhance the productivity of science
and health professionals, and the SciVal suite [http://www.scival.com ] and
MEDai’s Pinpoint Review [http://www.medai.com ], which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier
[http://www.elsevier.com ] employs 7,000 people worldwide. The company is
part of Reed Elsevier Group PLC [http://www.reedelsevier.com ], a
world-leading publisher and information provider, which is jointly owned by
Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock

        Media contact
        Harald Boersma
        Senior Manager Corporate Relations, Elsevier

SOURCE Elsevier

Source: PR Newswire